Entropy Neurodynamics

Entropy Neurodynamics R&D Expenses

The Research & Development Expenses of Entropy Neurodynamics (ENP.AX) as of Nov 22, 2026 is 3.25 M AUD. In the previous year, Research & Development Expenses was 2.40 M AUD — a change of 35.63% (higher).

R&D Expenses

3.25 MAUD

YoY

35.63%

Last updated:

Research & Development Expenses of Entropy Neurodynamics is 2026 3.25 M AUD. Research & Development Expenses of Entropy Neurodynamics was 2025 2.40 M AUD. It decreases by 35.63% higher compared to the previous year.

The Entropy Neurodynamics R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2019
496,688.00 AUD
Jan 1, 2020
2.62 M AUD
Jan 1, 2021
3.17 M AUD
Jan 1, 2022
2.54 M AUD
Jan 1, 2023
1.73 M AUD
Jan 1, 2024
1.96 M AUD
Jan 1, 2025
2.40 M AUD
Jan 1, 2026
3.25 M AUD
The Entropy Neurodynamics R&D Expenses history
YEARR&D ExpensesYoY
3.25 MAUD+35.63%
2.40 MAUD+22.62%
1.96 MAUD+12.92%
1.73 MAUD-31.67%
2.54 MAUD-19.93%
3.17 MAUD+20.89%
2.62 MAUD+427.34%
496,688.00AUD+527.42%
79,164.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics Stock analysis

What does Entropy Neurodynamics do? Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners. Entropy Neurodynamics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entropy Neurodynamics stock

Research & Development Expenses of Entropy Neurodynamics is 3.25 M AUD in 2026.

Research & Development Expenses of Entropy Neurodynamics changed from 2.40 M AUD to 3.25 M AUD, representing a 35.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Entropy Neurodynamics since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Entropy Neurodynamics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Entropy Neurodynamics

All Key Metrics — Entropy Neurodynamics